Vera Therapeutics (VERA) Projected to Post Quarterly Earnings on Wednesday

Vera Therapeutics (NASDAQ:VERA) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($1.34) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 12:30 PM ET.

Vera Therapeutics Price Performance

Shares of VERA opened at $41.76 on Monday. The company has a market cap of $2.92 billion, a P/E ratio of -10.47 and a beta of 1.16. The stock has a fifty day moving average price of $47.03 and a 200 day moving average price of $34.94. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $56.05.

Analyst Ratings Changes

VERA has been the topic of a number of analyst reports. Wedbush increased their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. The Goldman Sachs Group upped their target price on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Finally, Bank of America raised their target price on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $77.18.

Insider Activity at Vera Therapeutics

In other news, Director Patrick G. Enright acquired 5,882 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were bought at an average price of $42.50 per share, with a total value of $249,985.00. Following the purchase, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 16.30% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Several large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after buying an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Vera Therapeutics by 22.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after acquiring an additional 17,907 shares during the period. Jane Street Group LLC boosted its holdings in shares of Vera Therapeutics by 297.1% during the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after purchasing an additional 62,678 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Vera Therapeutics by 550.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after acquiring an additional 262,805 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Vera Therapeutics by 1.7% in the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after purchasing an additional 825 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.